OMOwen P. Martin

Owen P. Martin

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Owen P. Martin has a total of 19 co-authors. Here are the top co-authors by number of shared publications:

  • Adaeze Obinelo

    Division of Gastroenterology, Department of Medicine, Massachusetts General Hospital and Harvard Medical School, Boston, USA

    1 shared publication
  • Charlotte Costentin

    Division of Gastroenterology, Department of Medicine, Massachusetts General Hospital and Harvard Medical School, Boston, USA

    1 shared publication
  • Christopher Oetheimer

    Division of Gastroenterology, Department of Medicine, Massachusetts General Hospital and Harvard Medical School, Boston, USA

    1 shared publication
  • Edgar D. Charles

    Bristol Myers Squibb, Lawrenceville, USA

    1 shared publication
  • Emma C. Butler

    1 shared publication
  • Hailey B. Patel

    Division of Gastroenterology, Department of Medicine, Massachusetts General Hospital and Harvard Medical School, Boston, USA

    1 shared publication

Latest Publications

  • Top Cited Papers

    Single-cell atlas of human liver and blood immune cells across fatty liver disease stages reveals distinct signatures linked to liver dysfunction and fibrogenesis

    by Owen P. Martin, Michael S. Wallace, Christopher Oetheimer, Hailey B. Patel, Emma C. Butler, Lai Ping Wong, Pinzhu Huang, Joshua Elbaz, Charlotte Costentin, Shadi Salloum, et al.

    Immune cells play a central yet poorly understood role in metabolic dysfunction-associated steatotic liver disease and metabolic dysfunction-associated steatohepatitis (MASLD/MASH), a global cause of liver disease with limited treatment. Limited access to human livers and lack of studies across MASLD/MASH stages thwart identification of stage-specific immunological targets. Here we provide a unique single-cell RNA sequencing atlas of paired peripheral blood and liver fine-needle aspirates from a full-spectrum MASLD/MASH human cohort. Our findings included heightened immunoregulatory programs with MASH progression, such as enriched hepatic regulatory T cells, monocytic myeloid-derived suppressor cells, TREM2+S100A9+ macrophages and S100hiHLAlo type 2 conventional dendritic cells. Hepatic cytotoxic T cell functions increased with inflammation, but decreased with fibrosis, while acquiring an exhausted signature, whereas natural killer cell-driven toxicity intensified. Our dataset proposes immunological mechanisms for increased fibrogenesis and vulnerability to liver cancer and infections in MASH and provides a basis for a deeper understanding of human immunological dysfunction in chronic liver disease and a roadmap to new targeted therapies.